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Abstract
Preeclampsia is a disease characterized by hypertension and proteinuria in the third trimester of pregnancy. Preeclampsia is a
major cause of maternal mortality, and fetal death, especially in developing countries, but its aetiology remains unclear. Key
ﬁndings support a causal role of superﬁcial placentation driven by immune mal maladaptation, which then lead to reduced
concentrations of angiogenic growth factors and to an increase in placental debris in the maternal circulation resulting in a
maternal inﬂammatory response. Epidemiological research has consistently demonstrated a substantial familial predisposition
to preeclampsia. Unfortunately, the conquest of the genes explaining such a individual susceptibility has been proved to be a
hard task. However, genetics will also inform us about causality of environmental factors, and then serve as a tool to prioritize
therapeutic targets for preventive strategies.
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Introduction
Preeclampsia is a multisystemic disorder of un-
known aetiology, which occurs in around 5% of all
pregnancies. Preeclampsia can be manifested as a
maternal syndrome (hypertension, proteinuria with
or without other multi-systemic alterations), or as a
foetal syndrome (foetal growth restriction, diminished
amniotic ﬂuid, and altered oxygenation) (Sibai et al.
2005).
Preeclampsia has a big deleterious impact in the
maternal and foetus morbidity and mortality world-
wide, but mainly in developing countries. A recent,
systematic review indicated that hypertensive preg-
nancy disorders are the leading cause of maternal
death in Latin American and Caribbean countries
(25.7%, 7.9–52.4) (Khan et al. 2006).
The aetiology of preeclampsia is still unknown, but
it is accepted that susceptibility for its development
is given by the presence of complex gene–gene and
gene–environment interactions between the mother
and the foetus. Previous studies observational studies
have showed compelling evidence of the presence of
risk factors for preeclampsia such as nulliparity, family
history of preeclampsia or eclampsia, personal history
of a previous pregnancy with preeclampsia, increment
in the trophoblastic mass (multiple pregnancy, molar
pregnancy), paternity change between pregnancies,
age over 40 years, obesity, and some maternal chronic
conditions such as diabetes, chronic hypertension,
renal disease, autoimmune disease, antiphospholipid
syndrome, while other factors as smoking during
pregnancy, regular physical activity and prenatal C
and E vitamin ingestion have been considered as
potential protective factors (Duckitt and Harrington
2005; Sibai et al. 2005). However, recent clinical trials
using vitamin C and E supplementation, have called
into question some of these associations (Poston et al.
2006).
Nevertheless, considerable progress in the last
decade has led to a better understanding of the
physiopathology of preeclampsia, which is supposed
to be determined by two essential processes; the ﬁrst
givenby asuperﬁcial trophoblastic invasion and apoor
remodeling of the spiral arteries and of the maternal
decidua, leading to an inadequate placentation and
therefore to a poor placental oxygenation, and an
hypoxic environment. Findings that are, perhaps, the
responsible of the vasoconstriction and an increased
maternal arterial blood pressure, but also may be
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that would lead to the endothelial dysfunction
observed during the preeclampsia and all its deleter-
ious consequences (Roberts and Hubel 1999; Saftlas
et al. 2005). A substantial part of this process could be
consequence of an abnormal immune response to the
antigenic stimulus given by the foetal–placental graft
(Saftlas et al. 2005) (Figure 1).
Cytokines and preeclampsia
A normal pregnancy is accompanied by an inﬂamma-
tory response, which is exaggerated in the case of
preeclampsia, and it has been postulated that
endothelial dysfunction can be a part of this
exacerbated phenomenon (Roberts and Hubel
1999). Th1-type cytokines such as a-tumoral necrosis
factor (TNF-a), g-interferon (IFN-g) and interleukin
2 (IL-2) induce trophoblastic apoptosis, restrain
differentiation and invasion of trophoblast, and
thus may be involved in the incomplete invasion of
trophoblast to spiral arteries and shadow implantation
of placenta that are integral pathologies of pree-
clampsia (Dong et al. 2005). On the other side, Th2
cytokines such as IL-4 and IL-10, stimulate the
differentiation and proliferation of the trophoblast;
low levels of IL-10 have been reported on women
with preeclampsia compared to pregnant women with
normal arterial blood pressure, so high levels of Th1
and low levels of Th2 cytokines, through a Th41/Th2
imbalance, could lead to a functional injury of the
trophoblast in preeclampsia (Dong et al. 2005; Makris
et al. 2006).
The exaggerated inﬂammatory response towards
pregnancy could be a condition of genetically
susceptible women (Redman et al. 1999). A study
performed in white and African–American women
gathered in the USA, found that white women with
preeclampsia had a higher probability of carrying
the genotype FNT-a 2308A/A than white pregnant
women with normal blood pressure (odds ratio [OR]:
4.1; 95%CI: 1.1–15.3), but no association was found
in African–American women. Both white and
African–American women had with preeclampsia
had a higher probability of carrying the genotypes
for IL-1a 24845G/G (African–American women’s
OR: 11.7; white women’s OR 1.9) and 2899C/C
( A f r i c a n – A m e r i c a nw o m e n ’ sO R :5 . 9 ;w h i t e
women’s OR 2.3). No signiﬁcant differences regard-
ing the allelic distribution were found between
preeclamptic women and pregnant women with
normal blood pressure for the 21082A IL-10
polymorphism (Haggerty et al. 2005). Another
recent study performed in white and African–
American women from Brazil, analysed the possible
association between preeclampsia and the 2308
Figure 1. Mechanisms of placental development in uncomplicated pregnancies and of pathological placentation, as in preeclampsia.
N. C. Serrano 198TNFa, transforming growth factor-b1 (þ10; 25),
21082 IL-10, 2174 IL-6, and þ874 interferon-g
polymorphisms, observing a lower frequency for
the IL-10 21082G/G genotype in women with
preeclampsia than in the control group, and a lack
of association with the other studied polymorphisms
including the results of the meta-analysis for the
TNF-a (Daher et al. 2006)
HLA and preeclampsia
During pregnancy, the maternal immune system gets
in direct contact with the cells and tissues of the
semiallogenic foetus graft and so, mechanisms must
exist to modulate and moderate the immune
maternal response to such stimulus. The tropho-
blastic cells, originated in the foetus, do not express
classic human leukocyte antigens (HLA) of the Ia
and II classes, except for a weak expression of HLA-
C, and they express non-classic antigens of the Ib,
HLA-G, -F and -E classes (Saftlas et al. 2005;
Ishitani et al. 2003), so these molecules could be
involved in certain pregnancy complications such as
preeclampsia, intrauterine growth restriction, and
recurrent abortion. The HLA-G can inhibit T and
NK-mediated cellular lysis, through direct inter-
action with the ILT2, ILT4 and KIR2DL4 receptors,
so cells from the invasive trophoblast that do not
express HLA-Ib on their surface would be exposed
to NK-mediated cellular lysis; the strong expression
of HLA-G molecules by the invasive trophoblast
joined to the expression of HLA-E and HLA-F in
the placenta, could prevent this event. Proteins
coded by HLA-G are almost monomorphic, ﬁnding
that markedly contrasts with the Ia and II classes
of HLA, which are highly polymorphic. Regarding
the HLA-G, polymorphisms have been reported in
both the regulator region on the 50 end (50URR) and
the non-transcribed 30 region of the gene (30UTR).
Fifteen alleles have been recognized by the WHO
nomenclature committee for factors in the HLA
system; nevertheless, only ﬁve HLA-G proteins with
simple aminoacid substitutions have been described
in the literature, two of them a product of nucleotide
substitutions in exon 2 (deﬁning the G*0101 and
G*0103 alleles), one in exon 3 (deﬁning the alleles
G*1040 £ ), and another one in exon 4 (deﬁning the
g*0106 allele) (Hviid 2006).
Two studies have independently reported a risk
signiﬁcantly augmented for the development of
preeclampsia in women pregnant for the ﬁrst
time, when the foetuses are carriers of the
þ14/þ14bp HLA-G, postulating that this genotype
could lead to a diminished expression of HLA-G in
the placenta (Hviid 2006). Even so, the results have
not been reproducible in other studies; therefore
more evidence is required to clear the possible role
of HLA-G in the pathogenesis of preeclampsia.
Inheritance, genes and preeclampsia
Preeclampsia has a great genetic component deter-
mined by multiple genes, which has been evidenced
through twin concordance studies and family aggrega-
tion studies. A study developed in Swedish population
including monozygotic (MC) and dicygotic (DC)
twins classiﬁed by 13 polymorphic markers, found a
concordance for preeclampsia of 0.57 in MC twins
and 0.18 in DC twins, and a heritability of 54%
(Salonen et al. 2000)
Recently Nilsson et al. (2004), in a large family
aggregation study for preeclampsia with 1,188,207
live births in Swedish population analysed under a
quantitative genetics model, found that the genetic
effect was responsible for 31% (95%CI 9–45) of the
disease burden, while the non-shared environmental
effect was only responsible for 63% (95%CI 55–74)
and the common environmental effect was very low
and not signiﬁcant.
For complex diseases, the genome-wide scan
strategy has been used, with the aim of identifying
susceptibility loci for the development of the disease.
Genome scans developed in families with preeclamp-
sia from Australia, New Zealand, Iceland and Finland
have localized in chromosome 2 possible susceptibility
loci for the development of preeclampsia/eclampsia.
The mapped locus in the population from Australia
and New Zealand was named PREG1 and is possibly
the same locus found in Finnish population. A
posterior study using the ﬁne mapping strategy and
SNP analysis determined, in the PREG1 locus, two
signiﬁcant linkage peaks, 2p11 and 2p23. Analysing
the public databases, two genes located in those
regions and related to the physiopathology of
preeclampsia were chosen for the SNP analysis
(Fitzpatrick et al. 2004); the TACR1 gene which
codes for a vasoactive neuropeptide, neurokinin B
(NKB), and which concentration has been found
elevated in pregnancies complicated with preeclamp-
sia compared to normal pregnancies (Page et al.
2000), and the TCF7L1 gene, which codes for a
transcription factor that functions as a mediator in
the WNT signalling pathway and is antagonised by the
b-transforming growth factor signalling pathway. The
WNY signalling pathway contributes to the establish-
ment of the relationship between the blastocist and
the luminal uterine epithelium, and to the synthesis of
the extra-cellular matrix components associated to
decidualization (Paria et al. 2001).
Six SNPs for the TACR1 gene and ﬁve for the
TCF7L1 gene were genotyped in a group of families
that showed linkage in the ﬁne mapping analysis, two
SNPs showed signiﬁcant LOD scores, higher than 3,
one for each studied gene. Although, no evidence of
linkage disequilibrium (LD) was found under any of
the heredity models for any of the SNPs (Fitzpatrick
et al. 2004).
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to develop preeclampsia increases rapidly, specially
those genes found involved with the maternal
homeostatic and cardiovascular system, or related
to the regulation of the maternal inﬂammatory
response.
Nearly 50 maternal genes have been analysed; most
of these studies have been approaches to identify a
genetic association, comparing the frequencies of
genetic polymorphisms between cases and controls.
Although close to 50 different genes have been
studied, 70% of the publications revolve around eight
candidate genes, which have been analysed because
of their biologic plausibility in preeclampsia. Among
them there are genes that code for the rennin–
angiotensin system which regulate blood pressure
(angiotensinogen, angiotensin converting enzyme,
and angiotensin receptor), inherited thrombophilias
(Factor V Leiden V, prothrombin, and metilene-
tetrahydrofolate reductase), vasodilatation regulating
genes (endothelial nitric oxide synthase, eNOS) and
genes that code for pro-inﬂammatory cytokines
(FNT-a) (Chappell and Morgan 2006) (Table I).
In a large study from Colombia, we found that the
eNOS Glu298Asp polymorphism is associated with a
signiﬁcant increased risk of preeclampsia (p ¼ 0.001)
(Serrano et al. 2004).
Conclusion
Preeclampsia is a multisystemic disorder based in a
cascade of immunogenetic events apparently origi-
nated from an inadequate placentation. A unique
mechanism that explains the complexity of the
pathogenesis exists, and given so, neither does a single
marker that can predict the beginning of the disease.
Nevertheless, research strongly points to the recog-
nition of immunologic, biochemical and genetic
markers that could contribute to a better under-
standing of the disease and in ﬁnal to its prevention.
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